We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $542M
1-Year Est. Return 206.64%
This Fund
S&P 500
This Quarter Est. Return
+0.61%
1 Year Est. Return
+206.64%
3 Year Est. Return
+724.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$499M
AUM Growth
-$206M
Cap. Flow
-$143M
Cap. Flow %
-28.66%
Top 10 Hldgs %
71.5%
Holding
65
New
10
Increased
6
Reduced
11
Closed
15

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$8.13M
2
MRK icon
Merck
MRK
+$5.39M
3
JNJ icon
Johnson & Johnson
JNJ
+$5.26M
4
TERN
Terns Pharmaceuticals
TERN
+$4.3M
5
BIIB icon
Biogen
BIIB
+$3.4M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$27.4M
2
UGL icon
ProShares Ultra Gold
UGL
+$24.5M
3
QURE icon
uniQure
QURE
+$24.5M
4
SLNO
Soleno Therapeutics
SLNO
+$18.2M
5
VKTX icon
Viking Therapeutics
VKTX
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.81%
2 Miscellaneous 11.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$27.3B
$103M 20.59%
628,712
-53,500
-8% -$8.23M
ABVX
2
Abivax
ABVX
$10.4B
$66.9M 13.39%
600,747
– –
INSM icon
3
PUT
Insmed
INSM
$27.3B
$45.7M 9.16%
279,700
-140,300
-33% -$21.6M
LLY icon
4
Eli Lilly
LLY
$1T
$35.2M 7.04%
38,220
-12,280
-24% -$12.4M
TRVI icon
5
Trevi Therapeutics
TRVI
$2.4B
$24M 4.81%
2,013,602
– –
ARGX icon
6
argenx
ARGX
$63B
$21.7M 4.35%
29,739
-34,960
-54% -$27.4M
AZN icon
7
AstraZeneca
AZN
$248B
$18.8M 3.77%
95,376
– –
NAMS icon
8
NewAmsterdam Pharma
NAMS
$3.06B
$16.1M 3.23%
503,936
– –
DNTH icon
9
Dianthus Therapeutics
DNTH
$6.1B
$13.7M 2.74%
162,990
-42,100
-21% -$2.44M
RVMD icon
10
Revolution Medicines
RVMD
$44.4B
$12.2M 2.43%
124,990
+20,800
+20% +$2.1M
IONS icon
11
Ionis Pharmaceuticals
IONS
$9.42B
$10.8M 2.17%
144,376
– –
MRNA icon
12
CALL
Moderna
MRNA
$56B
$10.2M 2.03%
+200,000
New +$9.33M
EYPT icon
13
EyePoint Inc
EYPT
$393M
$9.89M 1.98%
767,098
– –
DGX icon
14
Quest Diagnostics
DGX
$26B
$8M 1.6%
40,817
– –
ALMS
15
Alumis Inc
ALMS
$1.37B
$7.16M 1.43%
+325,046
New +$8.13M
VKTX icon
16
Viking Therapeutics
VKTX
$3.93B
$5.88M 1.18%
180,731
-538,634
-75% -$17.3M
MRK icon
17
Merck
MRK
$366B
$5.62M 1.12%
+46,700
New +$5.39M
TERN
18
DELISTED
Terns Pharmaceuticals
TERN
$5.53M 1.11%
+104,800
New +$4.3M
JNJ icon
19
Johnson & Johnson
JNJ
$649B
$5.52M 1.11%
+22,600
New +$5.26M
SION
20
Sionna Therapeutics
SION
$330M
$4.8M 0.96%
119,741
– –
SRRK icon
21
Scholar Rock
SRRK
$6.99B
$4.73M 0.95%
96,285
– –
RAPP
22
Rapport Therapeutics
RAPP
$2.21B
$4.33M 0.87%
138,508
– –
ASND icon
23
Ascendis Pharma A/S
ASND
$17.7B
$4.06M 0.81%
17,740
– –
BLTE
24
Belite Bio
BLTE
$7.77B
$3.98M 0.8%
24,989
+7,000
+39% +$1.18M
XENE icon
25
Xenon Pharmaceuticals
XENE
$5.77B
$3.78M 0.76%
65,000
+25,000
+63% +$1.15M
1
2 3

Similar funds

CA
CV Advisors Aventura, Florida $542M AUM 24.89% 1-Year Est. Return
WCM
Westerly Capital Management San Francisco, California $542M AUM 48.48% 1-Year Est. Return
LI
Louisbourg Investments Dieppe, New Brunswick, Canada $542M AUM 21.44% 1-Year Est. Return
CWWM
Clear Wave Wealth Management Red Bank, New Jersey $541M AUM
FVCM
F&V Capital Management Boca Raton, Florida $542M AUM 46.38% 1-Year Est. Return
LI
Lafayette Investments Ashton, Maryland $542M AUM 22.5% 1-Year Est. Return
CCT
Chemung Canal Trust Elmira, New York $541M AUM 32.42% 1-Year Est. Return
MFS
Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

Artia Global Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Artia Global Partners held 65 positions worth $499M, down 29% from $706M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Artia Global Partners withdrew a net $143M in Q1 2026, closing 15 positions and reducing 11 holdings. Its most notable exit was ProShares Ultra Gold, an estimated $24.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 85% a quarter earlier, followed by Miscellaneous.

Against the trend, Artia Global Partners opened a new position in Alumis Inc worth $7.16M.

  • Artia Global Partners's largest Q1 2026 buy was Alumis Inc: 325,046 shares worth $7.16M.
  • Artia Global Partners added most to Revolution Medicines in Q1 2026, an estimated $2.1M increase.
  • Artia Global Partners's biggest Q1 2026 reduction was argenx, cutting an estimated $27.4M.
  • Artia Global Partners fully exited ProShares Ultra Gold in Q1 2026, selling an estimated $24.5M.
  • Artia Global Partners's ten largest holdings make up 72% of its $499M portfolio in Q1 2026.
  • Artia Global Partners opened 10 new positions and closed 15 in Q1 2026.
  • Artia Global Partners's portfolio value fell 29% quarter-over-quarter to $499M.

Based on Artia Global Partners's 13F filing for Q1 2026, filed 15 May 2026.